Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc.DFTX決算レポート

Nasdaq · biotechnology industry

Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.

DFTX Q4 2023 Key Financial Metrics

売上高

$906.0K

粗利益

N/A

営業利益

$-22.2M

純利益

$-23.9M

粗利益率

N/A

営業利益率

-2450.8%

純利益率

-2634.0%

前年比成長

-16.1%

EPS

$-0.58

資金フロー

Mind Medicine (MindMed) Inc. Q4 2023 財務サマリー

Mind Medicine (MindMed) Inc. reported revenue of $906.0K (down 16.1% YoY) for Q4 2023, with a net profit of $-23.9M (down 386.7% YoY) (-2634.0% margin). Cost of goods sold was N/A.

主要財務指標

総売上高$906.0K
純利益$-23.9M
粗利益率N/A
営業利益率-2450.8%
報告期間Q4 2023

Mind Medicine (MindMed) Inc. 年度売上推移

Mind Medicine (MindMed) Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $4.7M). Click any linked year to see what changed vs the prior 10-K.

年度年間売上
2023$4.7Mvs 2022
2022$1.5M

Mind Medicine (MindMed) Inc. 四半期売上・純利益の履歴

Mind Medicine (MindMed) Inc. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

四半期売上高売上前年比純利益純利益率
Q4 2023$906.0K-16.1%$-23.9M-2634.0%
Q3 2023$1.2M+223.1%$-17.9M-1541.1%
Q2 2023$1.3M+1498.8%$-29.1M-2222.0%
Q1 2023$1.3M+4855.6%$-24.8M-1932.6%
Q4 2022$1.1M$-4.9M-454.0%
Q3 2022$360.0K+662.5%$-16.5M-4579.2%
Q2 2022$82.0K$-17.0M-20679.3%
Q1 2022$-27.0K$-18.5M68337.0%

損益計算書

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023Q4 2023
売上高$-27000$82000$360000$1.1M$1.3M$1.3M$1.2M$906000
前年比成長N/AN/A662.5%N/A4855.6%1498.8%223.1%-16.1%

貸借対照表

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023Q4 2023
総資産$149.2M$134.3M$180.9M$170.0M$155.5M$142.1M$141.6M$124.5M
総負債$12.4M$9.8M$27.3M$19.1M$25.2M$36.1M$45.6M$46.4M
株主資本$136.8M$124.5M$153.6M$150.9M$130.3M$106.0M$96.0M$78.1M

キャッシュフロー

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023Q4 2023
営業CF$-12.9M$-15.1M$-9.3M$-12.8M$-13.3M$-13.8M$-16.6M$-20.6M